The co-occurrence of slow-wave sleep (SWS) deficits and IL-6 elevation manifests as a shared phenotypic feature in both populations with obstructive sleep apnea (OSA) and post-gynecologic oncology patients, suggesting the potential utility of SWS/IL-6 profiling as discriminative biomarkers for OSA screening within gynecologic cancer cohorts. The gene discussed is IL6; the disease is obstructive sleep apnea syndrome.